GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall: here’s why
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and